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THE VALUE OF ROUTINE BIOCHEMICAL TESTS IN
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BENIGN PANCREATIC TUMOURS
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Departments of Surgery and *Geriatric Medicine, Unioersity Hospital,
Umed, Sweden
(Receioed 15 January 1991)
The probability that routine hematological laboratory tests of liver and pancreatic function can
discriminate between malignant and benign pancreatic tumours, incidentally detected during operation,
was investigated. The records of 53 patients with a verified diagnosis of pancreatic carcinoma and 19
patients with chronic pancreatitis were reviewed with regard to preoperative total bilirubin, direct
reacting bilirubin, alkaline phosphatase, glutamyltranspeptidase, aminotransferases, lactic dehydroge-
nase and amylase. Multivariate and discriminant analysis were performed to calculate the predictive
value for cancer, using SYSTAT statistical package in a Macintosh II computer. Total and direct
reacting bilirubin and glutamyltranspeptidase were significantly higher in patients with pancreatic
carcinoma. However, only considerably increased levels of direct reating bilirubin were predictive of
pancreatic carcinoma.
KEY WORDS: Pancreas carcinoma, chronic pancreatitis, bilirubin, alkaline phosphatase, glutamyl-
transpeptidase, aminotransferases, lactic dehydrogenase, amylase
INTRODUCTION
The diagnosis of pancreatic cancer is often difficult, even in the symptomatic
patient1. Preoperatively the diagnosis usually is settled by means of computed
tomography (CT) or ultrasound (US) and fine needle aspiration cytology (FNA)2.
Pancreatic carcinoma is reported to be complicated by obstructive jaundice in 40-
70% of cases3. However, specific symptoms are usually lacking which brings only
about 10% of the patients with pancreatic carcinoma to curative resection at an
early stage of the disease.
Also in patients with a pancreatic tumour incidentally detected peroperatively,
the diagnosis of carcinoma or chronic pancreatitis is usually achieved by means of
FNA or histopathologic examination (HPE). However, although the clinical
findings point to a malignant tumour, no objective diagnostic verification is
obtained in some cases since rapid staining or frozen section technique are not
available. This raises the question, can routing biochemical serum assays of liver
function, bile metabolism and amylase aid in discriminating between a benign and
malignant pancreatic tumour?
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MATERIAL AND METHODS
The records of 72 consecutive patients who had a diagnosis of pancreatic carcinoma
(53 patients) or chronic pancreatitis (19 patients) verified by FNA and/or HPE
between March 1982 and May 1986 were reviewed. Patients with common duct
stones were excluded. The median age of the 42 women and 30 men was 70 years
(range 34-90 years).
TNM classification was used in the patients with carcinoma. Stage I was found in
9 patients, stage II in 9, stage III in 10 and stage IV in 18 patients. In 7 patients the
stage of the tumour was not available. The tumour was resected with curative intent
in seven patients.
The preoperative laboratory data collected from the records included total
bilirubin, direct-reacting bilirubin, alkaline phosphatase (S-ALP), glutamyltrans-
peptidase (S-GT) aminotransferases, lactic dehydrogenase (LD) and amylase. The
serum tests were performed according to the routines of the Clinical Chemistry
Laboratory. The assays were unmodified during the study period.
Statistics
Wilcoxon rank sum test
4 was used to compare laboratory data from the patients in
the cancer group and the pancreatitis group. Factor analysis calculation was
performed with varimax rotation to achieve and standardize an independent or
orthogonal score for the predictors. This score was then used for calculations with
the multiple general linear hypothesis program with models as described in text. All
calculations were performed in a Macintosh II computer using SYSTAT5.
RESULTS
The results are summarized in Table 1.
Pancreatic Cancer
Thirtyfive (66%) cancer patients had markedly elevated total bilirubin with mean
value 210pmol/L. Thirtyfour of these had the tumour in the head of pancreas. The
mean value of total bilirubin in the whole group of 53 cancer patients was 148pmol/
L. The corresponding values of direct reacting bilirubin was 130pmol/L and
82/zmol/L respectively. Also the mean values of S-ALP, S-GT, transferases and
LD were above the upper reference limit in the total group of patients. Elevation of
amylase with mean value 11,2pmol/L was found in 7 patients.
Fortyfour patients had the tumour in the head of pancreas, 8 in the body or tail
and in one the localization was not stated. Out of the 8 patients with the tumour in
the body or tail of the pancreas, elevated values of bilirubin were found in one
patient with liver metastases, S-ALP in 2, S-GT in 3, aminotransferases in 3 and
LD in 4 patients. Amylase was normal in all these patients.
Chronic Pancreatitis
Only three patients (16%) with chronic pancreatitis had elevated values of total149150 L. ATHLIN ETAL.
bilirubin. One of these (44pmol/L) had pronounced cirrhotic liver disease without
obstruction of extra hepatic ducts. Of the other two patients one was treated with
an endoprosthesis (74pmol/L) and one with a Whipple procedure (84pmol/L).
Direct reacting bilirubin values were elevated in two patients with pancreatitis. The
mean values of S-ALP, S-GT and transferases were above the upper limit of
normal in all patients with chronic pancreatitis. LD was elevated in 5 patients with
mean 11,1/mol/L but the mean value for the total group was within normal limits.
Amylase was measured in only 10 patients with pancreatitis and was elevated in two
of these (10,1 and 13,1/tmol/L). No false negative cancer diagnosis was made in
any of the pancreatitis patients.
Statistical Analysis
Mean values of total and direct reacting bilirubin and S-GT were higher in the
patients with pancreatic carcinoma and the differences were statistically significant
(p< 0.001 and p< 0.05, respectively). In 15 of the 19 patients (83%) with benign
disease total and direct-reacting bilirubin below manufacturers upper reference
limit. No significant differences were found in the other tests.
The multivariate analysis used for detection of predictive value of the biochemi-
cal parameters was based on data from 43 patients with complete data sets (34
with cancer and 9 with pancreatitis). Since the biochemical parameters used in this
study were correlated they could not be used in a multivariate model for prediction
without transformation. This was done with factor analysis where the first seven
principal components explained 99,1% of the total variance and biochemical
parameters were represented by one component except for direct reacting bilirubin
+ total bilirubin and ASAT + ALAT, which fell into the same components,
respectively. The scores of each patient on these principal components were then
used to calculate the independent predictive value for each biochemical parameter
and the results from the multivariate calculations can be seen in Table 2. The
results suggested that bilirubin may be of value in predicting cancer. Therefore, a
discriminant analysis was performed where predictive value for cancer, after the a
priori probability of cancer in this sample (0,79) was taken into account for each
observed level of direct reacting bilirubin, was calculated and the results are
displayed graphically in Figure 1. As can be seen only considerably increased levels
of direct reacting bilirubin indicated cancer.
Table 2 Predictive value for malignancy of seven orthogonal factor scores representing biochemical
parameters and gender. The model is calculated as a multiple linear regression with F-ratio 0.54 (p-
value 0.53)R 15%
Stand. regr. p-value
coefficient t-test
Tot bil + dir bil 0.29 0.08
S-GT 0.17 0.30
ASAT+
ALAT 0.08 0.58
Male gender 0.08 0.62
S-ALP -0.07 0.66
Amylase -0.04 0.81
LD -0.03 0.84BIOCHEMICAL TESTS IN PANCREATIC TUMORS 151
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Figure 1 Probability of cancer for observed levels of direct reacting bilirubin. The a priori probability
of cancer in this series is 0.79.
DISCUSSION
In some patients a pancreatic mass is incidentally found during operation.
Preoperative FNA with rapid staining or HPE with frozen section may be used to
obtain a morphologic diagnosis within a few minutes thereby guiding the choice of
further surgery. However, these techniques are not available in all hospitals.
This retrospective study was undertaken to investigate the use of routine
hematological laboratory tests to discriminate between malignant or benign pancrea-
tic masses. We found that most of the tests were elevated in both the cancer and
pancreatitis patients. Total and direct reacting bilirubin and GT were significantly
higher in the patients with pancreatic carcinoma compared to those with chronic
pancreatitis. In retrospective as well as in prospective studies on jaundiced patients
a frequent cause for the hyperbilirubinemia seems to be pancreatic carcinoma and
none, or only a few cases with chronic pancreatitis are reported6-8. This is in
accordance with the results in the present study in which only 3 out of 19 patients
with chronic pancreatitis had elevated bilirubin values. Furthermore, for one of the
3 cases the jaundice was caused by liver cirrhosis.
Fitzgerald et al.9 evaluated the techniques currently employed in the diagnosis of
pancreatic carcinoma. Of the hematologic routine tests, S-ALP had a high diagnos-
tic accuracy while bilirubin was elevated in only half of the patients with pancreatic152 L. ATHLIN ETAL.
carcinoma. Lindberg, in a consecutive series of 144 patients with jaundice, found
that in the differential diagnosis of pancreatic cancer and benign extrahepatic
obstruction, bilirubin was the fourth and S-ALP the fifth most powerful indicant.
Frebourg
1 did not find a diagnostic value for serum bilirubin in pancreatic cancer
and Di Mango
11 could not demonstrate specificity for elevated values of S-ALP and
bilirubin in excluding benign hepatic disorders.
In our study, factor and discriminant analysis demonstrated that only very high
levels of direct reacting bilirubin may serve to predict pancreatic carcinoma.
In a retrospective study
12 on 868 patients with inflammatory pancreatic disease
3% were jaundiced due to chronic pancreatitis and extrahepatic obstruction and
1.4% required surgical decompression. However, not only the magnitude but also
the duration and progression of the bilirubin levels should be taken into consider-
ation in the diagnosis of a pancreatic tumour
13 since a transitory periductular
pancreatic oedema may account for elevation of bilirubin even in some patients
with chronic pancreatitis12.
In the present study, S-ALP had elevated mean values in both the cancer patients
and pancreatitis patients but did not differ between these groups. Seligson
14 found
elevated S-ALP in 20 out of 24 patients with pancreatic malignancy which was
significantly more common than in patients with chronic pancreatitis. However,
elevation of S-ALP is not specific for pancreatic cancer since this can be found also
in patients with other gastrointestinal tract cancers. Furthermore, biliary duct
obstruction of any cause leads to elevation of S-ALP and may reflect that
condition rather than be a marker of a specific disease of the pancreas islets5.
Amylase was within the limits of the normal range in most of the patients in the
present study which is in accordance with the results presented by Fitzgerald
9 who
found elevated amylase activity in the serum of only 14% of patients with
pancreatic cancer, in 31% of patients with other gastrointestinal cancers and in 9%
of patients with chronic pancreatitis. Thus amylase seems of merit only in the
diagnosis of acute pancreatitis16.
The mean value of S-GT was above the upper reference limit in all patients in the
present study, and significantly higher in the cancer patients compared to the
pancreatitis patients. S-GT is distributed in different organs such as kidney, liver
and pancreas. A specific S-GT seems to be present in pancreatic carcinoma cells17.
Duct obstruction due to chronic pancreatitis increses S-GTTM. Collins et al.
19
demonstrated a low sensitivity and specificity of S-GT in the differential diagnosis
of jaundice.
In conclusion we found that jaundice was not frequent in patients with chronic
pancreatitis. Although an elevation in routine hematological laboratory tests of
liver and pancreatic function was common in the patients in the present study, only
considerably raised levels of direct reacting bilirubin seemed to be of value in
predicting cancer when a tumour was found in the head of pancreas. The
discrepancy in the results of different studies evaluating diagnostic accuracy of
routine biochemical tests in the diagnosis of pancreatic tumours may, to some
extent, be explained by differences in laboratory techniques and variability in
patients groups. In the individual patient, however, the final diagnosis and decision
of resection should be achieved by mean of FNA or HPE.BIOCHEMICAL TESTS IN PANCREATIC TUMORS 153
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INVITED COMMENTARY
The differentiation between chronic pancreatitis and pancreatic cancer can be a
difficult problem both preoperatively and intraoperatively, especially in an indivi-
dual patient with a relatively early cancer. A large amount of confusion has evolved
over the relationship between pancreatitis and pancreatic cancer mainly because
the word "pancreatitis" is often used to connote several clinical, operative-154 L. ATHLIN ETAL.
macroscopic appearances, and histopathologic findings. The relationship between
the two entities can be summarized as follows:
1. Patients with the acute or chronic form of pancreatitis of whatever etiology
(gallstones, alcohol, etc.) are not at increased statistical risk from developing
pancreatic cancer. The only notable rare exception is hereditary pancreatitis
starting in early life where it is well documented that the patients are at high
risk of developing pancreatic cancer in adult life.
2. Any patient with a pancreatic cancer or periampullary cancer (arising in the
ampulla, duodenum, or distal common bile duct) may present with an acute
episode or recurrent acute episode of documented clinical pancreatitis which
is backed up by acute elevations of serum amylase, lipase, etc.
3. Histopathologic evidence of pancreatic inflammation, glandular destruction,
and fibrosis, (i.e., pancreatitis), is invariably present in association with, and
is probably induced by, any pancreatic tumor. This may cause diagnostic
difficulties both pre-operatively and intraoperatively since the entire pancrea-
tic mass may be much larger than the actual cancer. Further, needle biopsy of
any mass will be subject to a varying degree of sampling error depending on
the actual size and site of the tumor relative to the entire inflammatory mass.
Given the above considerations, any simple blood test that could indicate
whether a neoplastic component is present in any pancreatic mass or not would
solve a major clinical dilemma. Drs. Athlin and colleagues have employed multi-
variant and discriminant analysis on routine laboratory tests of liver and pancreatic
function to discriminate between benign and malignant pancreatic lesions.
Although the numbers of patients studies are small (53 patients with pancreatic
carcinoma and 19 with chronic pancreatitis), they found that only considerably
increased levels of direct reacting bilirubin were predictive of pancreatic carci-
noma. What does this mean to the practicing physician? Simply stated, if a patient
has a persistently and progressive evidence of biliary obstruction, the diagnosis is
more likely to be pancreatic carcinoma than chronic pancreatitis. But the clinician
must also remember that statistics do not necessarily apply to the individual
patient. Thus, a patient with a small early pancreatic carcinoma may, on first
presentation, have only a mildly elevated bilirubin. Alternatively, a patient with
severe cicatrizing pancreatitis may have a highly elevated bilirubin level. Thus, the
treating surgeon has to take the overall clinical picture into consideration and, if his
index of suspicion for cancer is high enough, he may opt for a pancreatoduodenal
resection irrespective of laboratory values or even negative needle biopsy results.
Since the mortality of pancreatoduodenal resection is now in the region of one or
two percent in expert hands, a case can be made for resecting any moderately
suspicious lesion around the head of the pancreas irrespective of laboratory values
or biopsy results. A thorough prospective study of various enzymes, human
associated antigens, and pancreatic hormones, measured both in the systemic and
portal venous systems have failed to show any possible useful addition to our
diagnostic armamentarium 1.BIOCHEMICAL TESTS IN PANCREATIC TUMORS 155
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